Lawmakers urge OMB to revisit FDA user fee sequestration

A group of 74 legislators from the U.S. House of Representatives sent a (see BioCentury Extra, Nov. 4).

The letter notes that the sequestration of the agency's user fees does not decrease the federal budget deficit and is "detrimental to patients, regulatory science, and public health." The letter also notes that including user fees in sequestration "compromises the good faith" of industry. Under sequestration, industry paid about $85 million in user fees in FY13 that will not be made available to FDA. ...